Published in J Immunol on December 01, 1974
Determination of anti-DNA antibodies by a modified 125I-labelled DNA-binding test. Elimination of non-specific binding of DNA to non-immunoglobulin basic proteins by using an anionic detergent. Clin Exp Immunol (1976) 2.50
Dietary enrichment with the polyunsaturated fatty acid eicosapentaenoic acid prevents proteinuria and prolongs survival in NZB x NZW F1 mice. J Clin Invest (1981) 1.58
Anti-ssDNA and antinuclear antibodies in human malaria. Clin Exp Immunol (1982) 1.49
Ability of the xid gene to prevent autoimmunity in (NZB X NZW)F1 mice during the course of their natural history, after polyclonal stimulation, or following immunization with DNA. J Clin Invest (1982) 1.30
The role of the host immune response in the development of tissue lesions associated with African trypanosomiasis in mice. Clin Exp Immunol (1978) 1.05
The occurrence of antibodies against single-stranded DNA in the sera of patients with acute and chronic leukaemia. Clin Exp Immunol (1976) 0.98
Human African trypanosomiasis in a traveler: diagnostic pitfalls. Am J Trop Med Hyg (2012) 0.83
Autoantibodies in three populations of Burkitt's lymphoma patients. Clin Exp Immunol (1983) 0.83
CD5+ B lymphocytes are the main source of antibodies reactive with non-parasite antigens in Trypanosoma congolense-infected cattle. Immunology (1997) 0.82
Follow-up of antibodies against single-stranded DNA in patients with haematological malignancies. Clin Exp Immunol (1985) 0.81
Antibodies to calmodulin during experimental Trypanosoma brucei rhodesiense infections in rabbits. Immunology (1985) 0.78
Anti-immunoglobulins and heterophil agglutinins in experimental trypanosomiasis. Infect Immun (1980) 0.77
Detection and composition of immune complexes in experimental African trypanosomiasis. Infect Immun (1981) 0.75
The fatigue severity scale. Application to patients with multiple sclerosis and systemic lupus erythematosus. Arch Neurol (1989) 13.32
Ly-1 B cells: functionally distinct lymphocytes that secrete IgM autoantibodies. Proc Natl Acad Sci U S A (1984) 5.15
Therapy of lupus nephritis. Controlled trial of prednisone and cytotoxic drugs. N Engl J Med (1986) 4.01
The pathogenesis of autoimmunity in New Zealand black mice. Curr Top Microbiol Immunol (1974) 3.98
X-linked B-lymphocyte immune defect in CBA/HN mice. I. Studies of the function and composition of spleen cells. J Exp Med (1975) 3.70
Immunoregulatory aberrations in systemic lupus erythematosus. J Immunol (1978) 3.07
Cytokine gene expression after in vivo primary immunization with goat antibody to mouse IgD antibody. J Immunol (1991) 3.04
X-linked B-lymphocyte immune defect in CBA/N mice. II. Studies of the mechanisms underlying the immune defect. J Exp Med (1975) 3.03
The genetics of the immune response to a synthetic double-stranded RNA in a mutant CBA mouse strain. J Immunol (1973) 3.00
Failure of autologous mixed lymphocyte reactions between T and non-T cells in patients with systemic lupus erythematosus. Proc Natl Acad Sci U S A (1978) 2.94
Effects of thymectomy or androgen administration upon the autoimmune disease of MRL/Mp-lpr/lpr mice. J Immunol (1980) 2.89
Decline in suppressor T cell function with age in female NZB mice. J Immunol (1974) 2.79
Combination therapy with pulse cyclophosphamide plus pulse methylprednisolone improves long-term renal outcome without adding toxicity in patients with lupus nephritis. Ann Intern Med (2001) 2.77
Systemic autoimmune disease arises from polyclonal B cell activation. J Exp Med (1987) 2.71
Loss with age in NZB-W mice of thymic suppressor cells in the graft-vs-host reaction. J Immunol (1974) 2.45
Controlled trial of pulse methylprednisolone versus two regimens of pulse cyclophosphamide in severe lupus nephritis. Lancet (1992) 2.38
Selective loss of suppressor cell function in New Zealand mice induced by NTA. J Immunol (1977) 2.38
The pathogenesis of autoimmunity in New Zealand mice, I. Induction of antinucleic acid antibodies by polyinosinic-polycytidylic acid. Proc Natl Acad Sci U S A (1969) 2.31
Studies of immune functions of patients with systemic lupus erythematosus. I. Dysfunction of suppressor T-cell activity related to impaired generation of, rather than response to, suppressor cells. Arthritis Rheum (1979) 2.28
Network theory in autoimmunity. In vitro suppression of serum anti-DNA antibody binding to DNA by anti-idiotypic antibody in systemic lupus erythematosus. J Clin Invest (1981) 2.24
Methylprednisolone and cyclophosphamide, alone or in combination, in patients with lupus nephritis. A randomized, controlled trial. Ann Intern Med (1996) 2.17
DNA-binding assay for detection of anti-DNA antibodies in NZB-NZW F1 mice. J Immunol (1969) 2.13
B-lymphocyte alloantigens associated with systemic lupus erythematosus. N Engl J Med (1978) 2.11
Alterations in immunoregulatory T cell subsets in active systemic lupus erythematosus. J Clin Invest (1980) 2.06
Defective EBV-specific suppressor T-cell function in rheumatoid arthritis. N Engl J Med (1981) 2.05
Increased spontaneous activity of antibody-forming cells in the peripheral blood of patients with active SLE. Arthritis Rheum (1977) 2.03
Mapping of a gene causing familial Mediterranean fever to the short arm of chromosome 16. N Engl J Med (1992) 1.90
Studies of immune functions of patients with systemic lupus erythematosus. Complement-dependent immunoglobulin M anti-thymus-derived cell antibodies preferentially inactivate suppressor cells. J Clin Invest (1979) 1.87
Effect of murine cytomegalovirus on the in vitro responses of T and B cells to mitogens. J Immunol (1976) 1.84
The cellular and genetic basis of murine lupus. Immunol Rev (1981) 1.75
The clearance and localization of nucleic acids by New Zealand and normal mice. Clin Exp Immunol (1972) 1.74
Cyclophosphamide in lupus nephritis: a controlled trial. Ann Intern Med (1971) 1.70
The pathogenesis of autoimmunity in New Zealand mice. 3. Factors influencing the formation of anti-nucleic acid antibodies. Immunology (1971) 1.68
Hematologic aspects of systemic lupus erythematosus. Current concepts. Ann Intern Med (1977) 1.68
Abnormally elevated frequency of Epstein-Barr virus-infected B cells in the blood of patients with rheumatoid arthritis. J Clin Invest (1984) 1.63
Autoimmunity--a perspective. Annu Rev Immunol (1983) 1.62
NIH conference. Rheumatoid arthritis: evolving concepts of pathogenesis and treatment. Ann Intern Med (1984) 1.61
Mechanism of allograft rejection in New Zealand mice. I. Cell synergy and its age-dependent loss. J Immunol (1973) 1.59
NIH conference. Systemic lupus erythematosus: evolving concepts. Ann Intern Med (1979) 1.59
Dietary enrichment with the polyunsaturated fatty acid eicosapentaenoic acid prevents proteinuria and prolongs survival in NZB x NZW F1 mice. J Clin Invest (1981) 1.58
Induction of immunologic tolerance in older New Zealand mice repopulated with young spleen, bone marrow, or thymus. J Exp Med (1970) 1.58
The natural history and immunopathology of outbred athymic (nude) mice. Clin Immunol Immunopathol (1975) 1.57
Increased immunoglobulin-secreting cells in the blood of patients with active systemic lupus erythematosus. Am J Med (1980) 1.53
Approach to the study of the role of sex hormones in autoimmunity. Arthritis Rheum (1979) 1.51
Correlation between clinical activity of systemic lupus erythematosus and the amounts of DNA in DNA/anti-DNA antibody immune complexes. J Immunol (1982) 1.47
Presence of autoantibody for phospholipase inhibitory protein, lipomodulin, in patients with rheumatic diseases. Proc Natl Acad Sci U S A (1981) 1.47
Heterogeneity of immunoregulatory T-cell subsets in systemic lupus erythematosus. Correlation with clinical features. Am J Med (1982) 1.46
A defect of immunoregulatory T cell subsets in systemic lupus erythematosus patients demonstrated with anti-2H4 antibody. J Clin Invest (1987) 1.46
Studies of consomic mice bearing the Y chromosome of the BXSB mouse. J Immunol (1985) 1.44
Pathogenesis of autoimmunity in New Zealand mice. V. Loss of thymic suppressor function. Arthritis Rheum (1974) 1.42
Renal flares are common in patients with severe proliferative lupus nephritis treated with pulse immunosuppressive therapy: long-term followup of a cohort of 145 patients participating in randomized controlled studies. Arthritis Rheum (2002) 1.42
Fractionation of cells on a discontinuous Ficoll gradient. Study of subpopulations of human T cells using anti-T-cell antibodies from patients with systemic lupus erythematosus. J Clin Invest (1976) 1.41
Supressor cells in the graft vs host reaction. J Immunol (1973) 1.41
T cell abnormalities in NZB mice occur independently of autoantibody production. J Exp Med (1981) 1.40
Enhanced antibody response of mice to polyinosinic-polycytidylic acid by antithymocyte serum and its age-dependent loss in NZB-W mice. J Immunol (1973) 1.40
Studies of congenic MRL-Ipr/Ipr.xid mice. J Immunol (1983) 1.38
CS-A therapy in MRL-lpr/lpr mice: amelioration of immunopathology despite autoantibody production. J Immunol (1987) 1.38
Responder cells in the human autologous mixed lymphocyte reaction. J Clin Invest (1981) 1.37
Autoantibody to an immunoregulatory inducer population in patients with juvenile rheumatoid arthritis. J Clin Invest (1981) 1.37
The autologous mixed lymphocyte reaction in strains of mice with autoimmune disease. J Immunol (1980) 1.36
Human lymphocytes with either the OKT4 or OKT8 phenotype produce interleukin 2 in culture. J Clin Invest (1982) 1.33
Studies of T cell deletion and T cell anergy following in vivo administration of SEB to normal and lupus-prone mice. J Immunol (1993) 1.33
Relationship between systemic lupus erythematosus T cell subsets, anti-T cell antibodies, and T cell functions. J Clin Invest (1984) 1.32
Immunofluorescence studies on thymocytotoxic antibody from New Zealand Black mice. J Immunol (1974) 1.31
Cyclophosphamide: use in practice. Ann Intern Med (1974) 1.31
Ability of the xid gene to prevent autoimmunity in (NZB X NZW)F1 mice during the course of their natural history, after polyclonal stimulation, or following immunization with DNA. J Clin Invest (1982) 1.30
Sex differences in formation of anti-T-cell antibodies. Nature (1976) 1.30
Efficacy of immunosuppressive drugs in rheumatic diseases. Arthritis Rheum (1973) 1.30
Qualitative characteristics of anti-DNA antibodies in lupus nephritis. Arthritis Rheum (1975) 1.29
Genetic analysis of autoimmune gld mice. I. Identification of a restriction fragment length polymorphism closely linked to the gld mutation within a conserved linkage group. J Exp Med (1988) 1.28
Complement-dependent alterations in the handling of immune complexes by NZB/W mice. J Immunol (1975) 1.28
The human autologous mixed lymphocyte reaction. III. Immune circuits. J Immunol (1982) 1.27
A serum inhibitor of immune regulation in patients with systemic lupus erythematosus. J Clin Invest (1978) 1.27
The role of NZB-NZW F1 thymus in experimental tolerance and auto-immunity. Arthritis Rheum (1970) 1.27
Autoimmunity and increased c-myb transcription. Science (1984) 1.27
In vitro correction of the interleukin 2 defect of autoimmune mice. Eur J Immunol (1983) 1.27
Therapeutic studies in NZB-W mice. II. Relative efficacy of azathioprine, cyclophosphamide and methylprednisolone. Arthritis Rheum (1972) 1.27
Heterogeneity of human suppressor cells induced by concanavalin A as determined in simultaneous assays of immune function. J Immunol (1980) 1.26
Influenza immunization in systemic lupus eruthematosus. A double-blind trial. Ann Intern Med (1978) 1.26
Genetic studies in NZB mice. V. Recombinant inbred lines demonstrate that separate genes control autoimmune phenotype. J Exp Med (1981) 1.25
Complexity of the cytokine and antibody response elicited by immunizing mice with Plasmodium yoelii circumsporozoite protein plasmid DNA. J Immunol (1995) 1.24
Experimental infections with African Trypanosomes. VI. Glomerulonephritis involving the alternate pathway of complement activation. Am J Trop Med Hyg (1974) 1.23
Cell cycle analysis of lymphocyte activation in normal and autoimmune strains of mice. J Immunol (1982) 1.23
Purification of an acidic nuclear protein antigen and demonstration of its antibodies in subsets of patients with sicca syndrome. J Immunol (1977) 1.22
The reaction of SLE antibodies with native, single stranded RNA: radioassay and binding specificities. J Immunol (1978) 1.22
The human autologous mixed lymphocyte reaction. I. Suppression by macrophages and T cells. J Immunol (1981) 1.21
A double-blind controlled trial comparing cyclophosphamide, azathioprine and placebo in the treatment of lupus glomerulonephritis. Arthritis Rheum (1975) 1.20
C-reactive protein mediates the solubilization of nuclear DNA by complement in vitro. J Exp Med (1985) 1.20
Isolation of a cDNA clone corresponding to an X-linked gene family (XLR) closely linked to the murine immunodeficiency disorder xid. Nature (1985) 1.18
Study of lymphocyte subpopulations in normal humans and patients with systemic lupus erythematosus by fractionation of peripheral blood lymphocytes on a discontinuous Ficoll gradient. Clin Exp Immunol (1976) 1.17
Proliferation of anti-DNA-producing NZB B cells in a non-autoimmune environment. J Immunol (1986) 1.17
Spontaneous "autoimmune disease" in nude mice. J Immunol (1974) 1.16
Cerebrospinal fluid antibodies to neuronal cells: association with neuropsychiatric manifestations of systemic lupus erythematosus. Am J Med (1981) 1.16
NIH conference. Systemic lupus erythematosus: insights from animal models. Ann Intern Med (1984) 1.16
Ribavirin: efficacy in the treatment of murine autoimmune disease. Science (1977) 1.15
Oncogene expression in autoimmune and normal peripheral blood mononuclear cells. J Exp Med (1986) 1.15
The pathogenesis of autoimmunity in New Zealand mice. II. Acceleration of glomerulonephritis by polyinosinic-polycytidylic acid. Lab Invest (1970) 1.14
T cell receptor gene expression in autoimmune mice. J Immunol (1986) 1.14
Myxedema and coronary artery disease--a comparative autopsy study. Ann Intern Med (1968) 1.14